The most frequently reported adverse events (AEs) of GLP-1 RAs were gastrointestinal adverse drug reactions, including nausea, vomiting, and abdominal pain, which were closely related to activation of central and peripheral GLP-1 receptors ( In a recent network meta-analysis, overall GLP-1 RAs significantly increased the incidence of gastrointestinal AEs compared with placebo or conventional treatment, and the odds ratios for nausea, vomiting and diarrhea from GLP-1 RAs were 11.8 (95% CI, 2.8946.9), 51.7 (95% CI, 7.07415), and 4.93 (95% CI, 1.7514.7), respectively ( Methods Data sources This retrospective pharmacovigilance study was conducted based on the FDA Adverse Event Reporting System (FAERS) database
If switching is not an option, use a syringe with clearly marked half-unit increments and round to the nearest half-unit
As we navigate the complexities of health and well-being, lets collectively prioritize our health by choosing science-backed solutions
In this interview with Plastic Surgery Practice , Joely Kaufman, MD, a board-certified dermatologist, fellow of the American Academy of Dermatology, and director of Skin Associates of South Florida in Coral Gables, discusses findings from the study, Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss , presented at the 2025 American Society for Dermatologic Surgery Annual Meeting, and shares how plastic surgeons and other aesthetic providers are adapting their treatment algorithms to address the unique facial changes associated with GLP-1related weight loss
